Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cardiff Oncology, Inc.

3.88
+0.26007.18%
Post-market: 3.920.0383+0.99%19:48 EDT
Volume:1.15M
Turnover:4.43M
Market Cap:258.12M
PE:-4.22
High:3.93
Open:3.65
Low:3.61
Close:3.62
Loading ...

Cardiff Oncology's Phase 1b Trial for Breast Cancer Treatment Shows 40% Objective Response Rate

MT Newswires Live
·
03 Jun

Cardiff Oncology ‘highly encouraged’ by onvansertib data presented at ASCO

TIPRANKS
·
03 Jun

Cardiff Oncology Announces Positive Data From Investigator-Initiated Trial of Onvansertib in Combination With Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at Asco 2025

THOMSON REUTERS
·
03 Jun

Piper Sandler Remains a Buy on Cardiff Oncology (CRDF)

TIPRANKS
·
09 May

Craig-Hallum Sticks to Its Buy Rating for Cardiff Oncology (CRDF)

TIPRANKS
·
09 May

Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
09 May

Cardiff Oncology Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Cardiff Oncology Q1 EPS $(0.20) Misses $(0.19) Estimate, Sales $109.00K Beat $96.43K Estimate

Benzinga
·
09 May

Cardiff Oncology announces second patent for onvansertib combination

TIPRANKS
·
24 Apr

Cardiff Oncology Announces a Second Patent for the Treatment of Mcrc for Bev-NaÏVe Patients

THOMSON REUTERS
·
24 Apr

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

GlobeNewswire
·
24 Apr

Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment

MT Newswires Live
·
16 Apr

BRIEF-Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
16 Apr

Cardiff Oncology Inc - Additional Clinical Data From Crdf-004 Trial Expected in 1H 2025

THOMSON REUTERS
·
16 Apr

Cardiff Oncology Inc - Primary Endpoint Is Objective Response Rate, Secondary Endpoints Include Pfs, Dor, Safety

THOMSON REUTERS
·
16 Apr

Cardiff Oncology Announces Completion of Enrollment in Phase 2 Crdf-004 Trial Evaluating Onvansertib for the Treatment of First-Line Ras-Mutated Metastatic Colorectal Cancer

THOMSON REUTERS
·
16 Apr

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

GlobeNewswire
·
16 Apr

Cardiff Oncology initiated with a Buy at Lucid Capital

TIPRANKS
·
03 Apr

Cardiff Oncology Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
01 Mar

Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
28 Feb